Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency (CREAATE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
This is a Phase 3, multicenter, 3-part study, with 2 randomized, double-blind, placebo-controlled parts and an open-label extension part, to evaluate the efficacy and safety of orally administered deucrictibant XR tablet for prophylaxis, and deucrictibant soft capsule for on-demand treatment of angioedema attacks in adult participants aged ≥ 18 years with AAE-C1INH.
研究概览
地位
详细说明
The study consists of a Screening Period, during which eligibility is confirmed, a Part 1 Prophylaxis Double-blind Treatment Phase, a Part 2 On-demand, Double-blind Treatment Phase, and a Part 3 On-demand Open-label Extension Phase. Approximately 24 participants will be randomized in Part 1 into 2 parallel arms for a treatment period of 12 weeks. During the prophylaxis treatment period participants will receive blinded study drug (deucrictibant 40 mg XR or placebo randomized in a 1:1 ratio). Upon completion of Part 1, participants will roll-over into Part 2. In addition to rollover participants completing Part 1, new deucrictibant treatment-naïve participants will be enrolled directly into Part 2 and this may occur while Part 1 is ongoing. During the on-demand period participants will receive blinded study drug (deucrictibant 20 mg soft capsule or matching placebo randomized in a 1:1 ratio, 2-period, 2-treatment crossover design) for 2 qualifying AAE-C1INH attacks. Participants completing Part 2 may roll over into Part 3 where all AAE-C1INH attacks will be treated with open-label deucrictibant 20 mg soft capsule.
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名：Pharvaris Clinical Team
- 电话号码：0031-712-036-410
- 邮箱：clinicaltrials@pharvaris.com
学习地点
-
-
-
Sofia、保加利亚
- 招聘中
- Study Site
-
-
-
-
-
Edmonton、加拿大
- 招聘中
- Study Site
-
-
-
-
-
Budapest、匈牙利
- 招聘中
- Study Site
-
-
-
-
-
Ankara、土耳其（türkiye）
- 招聘中
- Study Site
-
-
-
-
-
Vienna、奥地利
- 招聘中
- Study Site
-
-
-
-
-
Berlin、德国
- 招聘中
- Study Site
-
Frankfurt am Main、德国
- 招聘中
- Study Site
-
Munich、德国
- 招聘中
- Study Site
-
-
-
-
-
Milan、意大利
- 招聘中
- Study Site 1
-
Milan、意大利
- 招聘中
- Study Site 2
-
Milan、意大利
- 招聘中
- Study Site 3
-
Padova、意大利
- 招聘中
- Study Site
-
Roma、意大利
- 招聘中
- Study Site
-
-
-
-
-
Auckland、新西兰
- 招聘中
- Study Site
-
-
-
-
-
Grenoble、法国
- 招聘中
- Study Site
-
Lille、法国
- 招聘中
- Study Site
-
Paris、法国
- 招聘中
- Study Site
-
-
-
-
-
Krakow、波兰
- 招聘中
- Study Site
-
-
-
-
-
Clayton、澳大利亚
- 招聘中
- Study Site
-
-
-
-
-
Basel、瑞士
- 招聘中
- Study Site
-
-
-
-
California
-
San Diego、California、美国、92093
- 招聘中
- Study Site
-
Walnut Creek、California、美国、94598,
- 招聘中
- Study Site
-
-
Missouri
-
St Louis、Missouri、美国、63130
- 招聘中
- Study Site
-
-
Pennsylvania
-
Hershey、Pennsylvania、美国、17033
- 招聘中
- Study Site
-
-
-
-
-
Bristol、英国
- 招聘中
- Study Site
-
Cambridge、英国
- 招聘中
- Study Site
-
Leicester、英国
- 招聘中
- Study Site
-
London、英国
- 招聘中
- Study Site
-
Newcastle upon Tyne、英国
- 招聘中
- Study Site
-
Plymouth、英国
- 招聘中
- Study Site
-
-
-
-
-
Amsterdam、荷兰
- 招聘中
- Study Site
-
-
-
-
-
Madrid、西班牙
- 招聘中
- Study Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Provision of written informed consent
- Male or female (sex at birth) aged ≥18 years
- Diagnosis of AAE-C1INH
- History of AAE-C1INH attacks prior to the Screening Visit.
- If underlying disease associated with AAE is present, the underlying disease must be stable throughout the duration of part 1.
- Reliable access and ability to use available therapy to effectively manage AAE- C1INH attacks.
- Female participants of childbearing potential must agree to the protocol-specified pregnancy testing and to be abstinent from heterosexual intercourse or to use an acceptable contraception method.
Females of non-childbearing potential (surgically sterile, or postmenopausal with ≥ 12 months amenorrhea and postmenopausal FSH confirmation) are not required to use contraception during the study.
• Capable of recording, without assistance, eDiary and ePRO data using an electronic device, as evidenced by the eDiary and ePRO training.
Exclusion Criteria:
- Participation in a clinical study with any other investigational drug within the last 30 days or within 5 half-lives of the investigational drug at the Screening Visit (whichever is longer).
- Receiving long-term prophylaxis (LTP) treatment for AAE-C1INH and satisfied with this treatment. Participants who are not satisfied (eg, tolerability issues, lack of efficacy) and have previously stopped LTP treatment for AAE-C1INH, for reasons other than participation in this study, can sign the ICF and begin the Screening Period only if their last dose of the treatment was received prior to the timepoint before the Screening Visit
- Any females who are pregnant, plan to become pregnant, or are currently breast-feeding
- Abnormal hepatic function
- Moderate or severe renal impairment
- Any clinically significant comorbidity or systemic dysfunction that would interfere with the participant's safety or ability to participate in the study.
- History of epilepsy and/or other significant neurological diseases
- Any clinically significant and uncontrolled gastrointestinal dysfunction that may impact study drug absorption
- Evidence of current alcohol or drug abuse
- Use of medications that are moderate and strong inhibitors of cytochrome P450 (CYP) 3A4, or strong inducers of CYP3A4 within the last 30 days or within 5 half-lives (whichever is longer) at the time of the Screening Visit
- Known hypersensitivity to deucrictibant or any of the excipients of the study drug
- Use of angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing medications with systemic absorption within 5 half-lives before the Screening Visit
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：第一部分 - 第一组 - 积极治疗
|
Part 1: Deucrictibant 40 mg extended-release tablet for once daily oral use Part 2: Deucrictibant 20 mg soft capsule oral use Part 3: Deucrictibant 20 mg soft capsule oral use |
|
安慰剂比较：第 1 部分 - 第 2 组 - 安慰剂
|
Part 1: Placebo Comparator tablet for once daily oral use Part 2: Placebo Comparator soft capsule oral use |
|
实验性的：第2部分 - 第1组
|
Part 1: Deucrictibant 40 mg extended-release tablet for once daily oral use Part 2: Deucrictibant 20 mg soft capsule oral use Part 3: Deucrictibant 20 mg soft capsule oral use Part 1: Placebo Comparator tablet for once daily oral use Part 2: Placebo Comparator soft capsule oral use |
|
实验性的：第 2 部分 - 第 2 组
|
Part 1: Deucrictibant 40 mg extended-release tablet for once daily oral use Part 2: Deucrictibant 20 mg soft capsule oral use Part 3: Deucrictibant 20 mg soft capsule oral use Part 1: Placebo Comparator tablet for once daily oral use Part 2: Placebo Comparator soft capsule oral use |
|
实验性的：第 3 部分 - 开放标签
|
Part 1: Deucrictibant 40 mg extended-release tablet for once daily oral use Part 2: Deucrictibant 20 mg soft capsule oral use Part 3: Deucrictibant 20 mg soft capsule oral use |
研究衡量的是什么？
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Part 1: Time-normalized number of Investigator-confirmed AAE-C1INH attacks during Treatment Phase
大体时间：12 weeks
|
12 weeks
|
|
Part 2: Time to symptom relief, Patient Global Impression of Change (PGI-C) rating of at least "better"
大体时间：12 hours post-treatment
|
12 hours post-treatment
|
|
Part 3: Incidence of treatment-emergent adverse events (TEAEs), treatment-emergent adverse events of special interest (AESIs), and serious adverse events (SAEs)
大体时间：Through study termination, an average of 36 weeks
|
Through study termination, an average of 36 weeks
|
|
Part 3: Number of participants with clinically significant changes from baseline in Hematology parameters
大体时间：Through study termination, an average of 36 weeks
|
Through study termination, an average of 36 weeks
|
|
Part 3: Number of participants with clinically significant changes from baseline in Urinalysis parameters
大体时间：Through study termination, an average of 36 weeks
|
Through study termination, an average of 36 weeks
|
|
Part 3: Number of participants with clinically significant changes from baseline in Biochemistry parameters
大体时间：Through study termination, an average of 36 weeks
|
Through study termination, an average of 36 weeks
|
|
Part 3: Number of participants with clinically significant changes from baseline in vital signs
大体时间：Through study termination, an average of 36 weeks
|
Through study termination, an average of 36 weeks
|
|
Part 3: Number of participants with clinically significant changes from baseline in physical examinations
大体时间：Through study termination, an average of 36 weeks
|
Through study termination, an average of 36 weeks
|
|
Part 3: Number of participants with clinically significant changes in electrocardiogram (ECG)
大体时间：Through study termination, an average of 36 weeks
|
Through study termination, an average of 36 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Part 1: Proportion of participants who are AAE-C1INH attack-free during Treatment Phase
大体时间：12 weeks
|
12 weeks
|
|
|
Part 1: Time-normalized number of Investigator-confirmed AAE-C1INH attacks treated with on-demand medication during Treatment Phase
大体时间：12 weeks
|
12 weeks
|
|
|
Part 1: Time-normalized number of Investigator-confirmed moderate or severe AAE-C1INH attacks during Treatment Phase
大体时间：12 weeks
|
12 weeks
|
|
|
Part 1: Time-normalized number of Investigator-confirmed severe AAE-C1INH attacks during Treatment Phase
大体时间：12 weeks
|
12 weeks
|
|
|
Part 1: Proportion of participants achieving ≥50%, ≥70% and ≥90% reduction in AAE-C1NH attack rate relative to baseline during Treatment Phase
大体时间：12 weeks
|
12 weeks
|
|
|
Part 1: Incidence of TEAEs, treatment-emergent AESIs, and SAEs
大体时间：12 weeks
|
12 weeks
|
|
|
Part 1: Number of participants with clinically significant changes from baseline in Hematology parameters
大体时间：12 weeks
|
12 weeks
|
|
|
Part 1: Number of participants with clinically significant changes from baseline in Urinalysis parameters
大体时间：12 weeks
|
12 weeks
|
|
|
Part 1: Number of participants with clinically significant changes from baseline in Biochemistry parameters
大体时间：12 weeks
|
12 weeks
|
|
|
Part 1: Number of participants with clinically significant changes from baseline in Vital signs
大体时间：12 weeks
|
12 weeks
|
|
|
Part 1: Number of participants with clinically significant changes from baseline in physical examination
大体时间：12 weeks
|
12 weeks
|
|
|
Part 1: Number of participants with clinically significant changes from baseline in ECG parameters
大体时间：12 weeks
|
12 weeks
|
|
|
Part 1: Pre-dose plasma concentrations of Deucrictibant
大体时间：At Weeks 6 and 12
|
Deucrictibant plasma concentrations will be analyzed using liquid chromatography-mass spectrometry/mass spectrometry methods |
At Weeks 6 and 12
|
|
Part 1: Pre-dose plasma concentrations of deucrictibant metabolites
大体时间：At Weeks 6 and 12
|
Deucrictibant metabolites plasma concentrations will be analyzed using liquid chromatography-mass spectrometry/mass spectrometry methods |
At Weeks 6 and 12
|
|
Part 1: Pharmacokinetics [PK]: Urine concentrations of Deucrictibant and deucrictibant metabolites
大体时间：At Week 12
|
At Week 12
|
|
|
Part 1: Change from baseline in Angioedema Quality of Life (AE-QoL) questionnaire total score, functioning domain score, and fears/shame domain score
大体时间：Baseline (Day 1) and at Weeks 4, 8 and 12
|
The AE-QoL is a short 17-item questionnaire designed to retrospectively assess HRQoL, with a recall period of 4 weeks. Its results can be displayed as a total score or as 4 domain scores. The scores range from 0 to 100, after linear transformation of raw values, with higher scores indicating higher HRQoL impairment. |
Baseline (Day 1) and at Weeks 4, 8 and 12
|
|
Part 1: Change from baseline in Angioedema Control Test 4-week version (AECT-4wk)
大体时间：Baseline (Day 1) and at Week 12
|
AECT-4wk measures disease control retrospectively, it comprises 4 questions over a 4-week recall period. Scores for the responses in the AECT range from 0 to 16, with higher scores indicating better disease control (≤ 9 poorly controlled; ≥ 10 well controlled) |
Baseline (Day 1) and at Week 12
|
|
Part 1: Patient Global Assessment-Status (PGA-S) at baseline
大体时间：At Baseline (Day 1)
|
PGA-Status assesses on a 5-point scale how the participant's QoL has been impacted by AAE-C1INH since start taking the study drug |
At Baseline (Day 1)
|
|
Part 1: Patient Global Assessment of Change (PGA-Change) at Week 12
大体时间：At Week 12
|
PGA-Change assesses on a 5-point scale how the participant's QoL has been impacted by AAE-C1INH since start taking the study drug |
At Week 12
|
|
Part 1: Change from baseline in EuroQol 5 Dimension 5 level (EQ 5D 5L)
大体时间：Baseline (Day 1) and at Week 12
|
EQ 5D 5L is a brief, multiattribute, generic, health status measure composed of 5 questions with Likert response options (descriptive system) and a visual analog scale (EQ-VAS). The latter asks patients to rate their own health from 0 to 100 (the worst and best imaginable health, respectively) |
Baseline (Day 1) and at Week 12
|
|
Part 2: Time to complete symptom resolution, Patient Global Impression of Severity (PGI-S) rating of "no symptoms
大体时间：sustained within 24 hours post-treatment
|
sustained within 24 hours post-treatment
|
|
|
Part 2: Time to symptom relief defined as PGI-S rating of at least 1 point reduction
大体时间：12 hours post-treatment
|
12 hours post-treatment
|
|
|
Part 2: Proportion of study drug-treated attacks achieving complete symptom resolution defined as achieving PGI- S rating of "no symptoms"
大体时间：At 24 hours post-treatment
|
At 24 hours post-treatment
|
|
|
Part 2: Time to onset of symptom relief, defined as PGI-C rating of at least "a little better"
大体时间：Within 12 hours post-treatment
|
Within 12 hours post-treatment
|
|
|
Part 2: Time to End of Progression (EoP) in attack symptoms
大体时间：Within 12 hours post-treatment
|
EOP is defined as the earliest post-treatment timepoint after which all subsequent PGI-C ratings are stable or improved |
Within 12 hours post-treatment
|
|
Part 2: Incidence of TEAEs, treatment-emergent AESIs, and SAEs
大体时间：Up to 24 weeks
|
Up to 24 weeks
|
|
|
Part 2: Number of participants with clinically significant changes from baseline in Hematology parameters
大体时间：24 weeks
|
24 weeks
|
|
|
Part 2: Number of participants with clinically significant changes from baseline in Urinalysis parameters
大体时间：24 weeks
|
24 weeks
|
|
|
Part 2: Number of participants with clinically significant changes from baseline in Biochemistry parameters
大体时间：24 weeks
|
24 weeks
|
|
|
Part 2: Number of participants with clinically significant changes from baseline in Vital signs
大体时间：24 weeks
|
24 weeks
|
|
|
Part 2: Number of participants with clinically significant changes from baseline in physical examination
大体时间：24 weeks
|
24 weeks
|
|
|
Part 2: Number of participants with clinically significant changes from baseline in ECG parameters
大体时间：24 weeks
|
24 weeks
|
|
|
Part 2: Pharmacokinetics [PK]: Deucrictibant and deucrictibant metabolites plasma concentration-time profiles
大体时间：Day 1
|
Day 1
|
|
|
Part 3: Time to symptom relief, as PGI-C rating of at least "better"
大体时间：12 hours post-treatment
|
12 hours post-treatment
|
|
|
Part 3: Time to symptom relief, as PGI-S rating of at least 1 point reduction
大体时间：12 hours post-treatment
|
12 hours post-treatment
|
|
|
Part 3: Proportion of study drug-treated attacks achieving complete symptom resolution, defined as achieving PGI-S rating of "no symptoms"
大体时间：24 hours post-treatment
|
24 hours post-treatment
|
合作者和调查者
调查人员
- 研究主任：Study Director, Pharvaris、Pharvaris Netherlands B.V.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- PHA022121-C308
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.